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SUMMARY – Castleman’s disease (in the literature also known as angiofollicular hyperplasia) 
is a rare benign lymphoproliferative disease. Clinically, it can manifest as unicentric or multicentric 
disease. Unicentric disease is most often diagnosed by accident or by symptomatology resulting from 
compression upon the adjoining anatomical structures. Considering its lymphatic origin, tumor 
mass can theoretically occur in any body region. We present a case of paracardiac localization of 
unicentric Castleman’s disease in a previously healthy 24-year-old woman. In such clinical cases, the 
specific localization of the tumor and its radiological properties can pose a differential diagnostic 
dilemma. Correct diagnosis is only possible after complete surgical excision and histopathologic 
analysis, which is the optimal therapeutic approach in this disease.
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Introduction
Castleman’s disease (in the literature also known 
as angiofollicular hyperplasia) is a rare benign lym-
phoproliferative disease. Clinically, it can manifest as 
unicentric (UCD) or multicentric (MCD) Castelman’s 
disease. The number of people diagnosed with Castel-
man’s disease each year is not well known, but it is es-
timated that there are approximately 6500 to 7700 new 
cases per year in the US1. The estimated US 10-year 
prevalence of MCD was 2.4 per million2. The patho-
genesis of the disease is not fully understood. Overpro-
duction of interleukin-6 (IL-6) in UCD and both IL-6 
and infection with human herpes virus 8 (HHV-8) 
in MCD have been described as the main etiologic 
factors3,4. Deregulated and overproduced IL-6, par-
ticularly in patients with MCD, stimulates the produc-
tion of acute phase reactants in the liver, resulting in 
constitutional symptoms including fever, sweats and 
fatigue, and laboratory anomalies such as anemia, el-
evated inflammatory markers, hypergammaglobuline-
mia and hypoalbuminemia5. IL-6 also stimulates B-
cell proliferation and survival. Additionally, it induces 
the expression of vascular endothelial growth factor 
and increased angiogenesis5. HIV-associated MCD is 
uniformly associated with HHV-8 infection, although 
its prevalence in HIV-negative MCD varies by the lo-
cal prevalence rate of HHV-8. Plasma levels of HHV-8 
DNA correlate with clinical symptoms and predict re-
lapse rates in HIV-associated MCD6. In patients with 
HHV-8 positive MCD, HHV-8 infected vascular and 
lymphoid cells express viral analog of IL-6 (vIL-6) thus 
contributing to the pathogenesis.
Diagnosis of the disease is made by excisional biop-
sy of affected lymph node tissue. In cases of deeper and 
less accessible disease, core needle biopsy is preferred 
over fine needle aspiration, since fine needle aspiration 
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is insensitive for both UCD and MCD5. Castleman’s 
disease can be divided into 3 histopathologic subtypes: 
1) hyaline-vascular (the most common, 80%-90% of 
all cases), 2) plasmacellular (10%-20% of cases), and 
3) mixed type7. UCD is common in younger patients 
that are in their 3rd or 4th decade of life7. It usually 
progresses without symptoms and is characterized by 
a relatively large, i.e. bulky, slowly growing tumorous 
mass. UCD is most often diagnosed by accident or by 
symptomatology resulting from compression upon the 
adjoining anatomical structures. Considering its lym-
phatic origin, tumor mass can theoretically occur in 
any body region. However, the most common localiza-
tion is mediastinum, more specifically anterior medi-
astinum, right paratracheal, lung hilum and posterior 
mediastinum3. The patient may sometimes experience 
nonspecific disturbances similar to B symptoms such 
as weight loss, loss of appetite, night sweats, fever that 
is sometimes accompanied by increased erythrocyte 
sedimentation rate, increase of serum C-reactive pro-
tein concentration and polyclonal gammopathy on 
serum protein electrophoresis. All these symptoms 
are the result of increased IL-6 production, and are 
almost exclusively associated with the plasmacellular 
histologic subtype3,8. Therapy of choice for unicentric 
form of the disease is total surgical excision of the 
tumor with very low incidence of relapse8,9. For the 
disease that cannot be completely excised, radiation 
therapy is recommended10,11. In selected patients who 
are not candidates for surgical resection or radiother-
apy, partial resection or clinical observation alone can 
be sufficient. However, if the disease becomes symp-
tomatic, systemic treatment should be considered5.
Multicentric Castleman’s disease is more typical 
in older patients (6th decade of life) or in HIV posi-
tive patients regardless of age3,10. HIV infection is an 
important risk factor for MCD, and all patients with 
HIV-associated MCD are coinfected with HHV-85. 
Systemic inflammatory manifestations similar to B 
symptoms (fever, night sweats, weight loss and fa-
tigue) characterize the vast majority of MCD patients. 
The usual findings during physical examination are 
general lymphadenopathy, hepatosplenomegaly, with 
many patients presenting with fluid retention (lower 
extremity edema, pleural or pericardial effusions, or 
ascites). Common hematologic abnormalities include 
anemia, elevated inflammatory markers (erythrocyte 
sedimentation rate and C-reactive protein), hyper-
gammaglobulinemia and hypoalbuminemia. The pre-
sentation of the disease can vary ranging from indo-
lent or slow progressing to acute and fulminant. Some 
patients may experience relapsing-remitting course of 
the disease5,12. In case of concomitant infection with 
HIV and HHV-8, additional symptomatology is 
possible (low T-cell CD4 count, opportunistic infec-
tions, occurrence of Kaposi sarcoma or primary effu-
sion lymphoma, etc.). The recommended treatment of 
choice is systemic monotherapy with the anti-CD20 
monoclonal antibody rituximab12-15. Therapy with 
glucocorticoids offers short-term control of the symp-
toms, however, complete remissions are rare and short-
lived3,16. In patients with coinfection with HIV and/or 
HHV-8, antiretroviral therapy together with antiviral 
therapy (valgancyclovir or gancyclovir) should also be 
initiated. As second-line treatment in HIV negative 
patients, the anti-IL-6 monoclonal antibody siltux-
imab is recommended5. Further lines of treatment 
involve administration of single-agent or combination 
of chemotherapeutics (etoposide, vinblastine or lipo-
somal doxorubicin). Currently, there are clinical trials 
investigating therapy with siltuximab and tocilizumab 
in HIV positive MCD5.
Case Report
A previously healthy 24-year-old woman was ob-
served at Surgical Emergency Unit of the Split Uni-
versity Hospital Center because of protracted back 
pain that occurred 2 days earlier when she suffered a 
traffic accident. As part of diagnostic workup, chest 
radiography was performed. It showed a suspect tu-
morous mass localized in the anterior mediastinum. 
Urgent investigation was further extended by multi-
slice computed tomography imaging (MSCT) of the 
thorax and transthoracic echocardiography that raised 
suspicion of left ventricle pseudoaneurysm (Fig. 1). 
The patient was hospitalized at the Department of 
Cardiology, Split University Hospital Center. Using 
MSCT angiography, the mass was characterized as 
a well vascularized, irregular, expansive tumor local-
ized adjacent to the left ventricle, measuring 3x6.3 
cm in diameter. Thus, the diagnosis of left ventricle 
pseudoaneurysm was excluded and the mass showed 
properties similar to hemangioma. Imaging analysis 
Acta Clin Croat,  Vol. 55,   No. 1,  2016 163
I. Vuković et al. Paracardiac Castleman’s disease
was further extended by digital subtraction angiogra-
phy (DSA), which also showed exceptional vascular-
ization of the tumor (Fig. 2). Cranial portion of the 
tumor was irrigated from the left internal thoracic ar-
tery (mammary artery), while caudal portion received 
arterial supply from celiac trunk. Venous branches 
were part of the left brachiocephalic trunk basin. By 
using magnetic resonance imaging of the heart, the 
neoplasm was visualized as a solid mass with smooth 
contours, very well imbibed and vascularized, without 
signs of myocardial and/or pericardial invasion (Fig. 
3). Finally, the early diagnosis of hemangioma was 
established and the cardiology-cardiac surgery team 
made a decision to perform full excision of the tumor. 
The operation was performed successfully and with-
out further complications (Fig. 4). Histopathologic 
Fig. 1. Transthoracic echocardiography image showing 
paracardiac tumor mass (within ellipse, marked by ar-
row) adjacent to the left ventricle (LV) – panel A.  The 
tumor was well vascularized, pulsed Doppler flow-line 
spectrum indicating low resistance flow – panel B.
Fig. 2. Digital subtraction angiography showing vascu-
larization of the tumor. Cranial portion of the tumor was 
irrigated from the left internal thoracic artery (LIMA), 
corresponding to feeding artery indicated by the arrow –
panel A. Caudal portion received arterial supply from celiac trunk – Panel B. Venous branches were part of the left bra-
chiocephalic trunk basin – panel C.
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Fig. 3. Magnetic resonance imaging of the heart and paracardiac tumor mass (indicated by arrow). Panel A shows T1 
weighted sequence, panel B T2 weighted sequence, panel C turbo inversion recovery magnitude (TIRM) sequence, and 
panel D true fast imaging with steady state free precession (TRUFI) sequence.
Fig. 4. Macroscopic appearance of the tumor after exci-
sion.
analysis of the tumor showed the lymph node tissue 
that had features characteristic of the hyaline-vascular 
type of Castleman’s disease (Fig. 5). Currently, the 
patient undergoes regular medical check-ups and she 
is without any symptoms and signs of relapse of the 
disease.
Conclusion
Castleman’s disease is a very rare entity and thus 
there is a scarce number of epidemiological studies. 
Mediastinal localization has been presented in the 
majority of published cases. However, paracardiac lo-
calization has not been described previously. In this 
clinical case, specific localization of the tumor and its 
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Fig. 5. Histopathologic appearance of the tumor tissue. Panel A: lymphoid follicle with partially involuted germinal cen-
tre and penetrating arteriole surrounded by concentric layers of small, uniform lymphocytes (hematoxylin and eosin stain, 
magnification 400×); panel B: interfollicular zone: numerous blood vessels with hyperplastic endothelial cells surrounded 
by cuffs of collagen (hematoxylin and eosin stain, magnification 100×).
radiological properties can pose a differential diag-
nostic dilemma and can clinically impose as (pseudo)
aneurysm of the left ventricle or hemangioma. There-
fore, correct diagnosis is only possible after complete 
surgical excision and histopathologic analysis, which 
in this case is the optimal therapeutic approach.
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Sažetak
CASTLEMANOVA BOLEST KOJA SE PREZENTIRALA KAO TUMORSKA PARAKARDIJALNA 
TVORBA
I. Vuković, T. Brešković, D. Duplančić, T. Batinić, I. Štula, C. Bulat i S. Tomić
Castlemanova bolest (u literaturi još poznata kao angiofolikularna hiperplazija) je rijetka limfoproliferativna bolest 
dobroćudnog tijeka. Klinički se manifesira kao lokalizirana i multicentrična. Dijagnoza lokalizirane bolesti se najčešće po-
stavlja slučajno nakon obrade simptomatologije uzrokovane kompresijom tvorbe na okolne anatomske strukture. S obzirom 
na njeno limfatičko podrijetlo tumorska masa se može pojaviti u bilo kojem dijelu tijela. Prikazujemo slučaj parakardijalno 
lokalizirane Castlemanove bolesti kod prethodno zdrave 24-godišnje žene. U ovakvom slučaju, zbog specifične lokalizacije 
i radioloških obilježja tvorba može predstavljati diferencijalno dijagnostičku dilemu. U tom slučaju točna dijagnoza je mo-
guća tek nakon potpune kirurške ekscizije i patohistološke analize, što u slučaju ove bolesti ujedno predstavlja optimalan 
terapijski pristup.
Ključne riječi: Limfni čvorovi, hiperplazija; Limfne žile; Tumori; Rijetke bolesti; Prikazi slučaja
